Osteoporosis | Treatment Algorithms | Claims Data Analysis | US | 2019
A wide array of drugs are available to treat osteoporosis. These drugs are generally effective in reducing patients’ risk of fracture and are well tolerated. Oral bisphosphonates, especially alendronate, dominate first-line treatment, mainly because of the drug class’s widespread generic availability and physician familiarity. Branded agents—Amgen’s Prolia, Eli Lilly’s Forteo, and Radius Health’s Tymlos—are reserved for later lines of therapy, primarily because of their higher prices. This report presents insight into the treatment of a disease in which brands compete for market share in the second and later lines of therapy and combination use is minimal.
QUESTIONS ANSWERED
What patient share do key therapies and brands garner by line of therapy in newly diagnosed osteoporosis patients?
What are the quarterly trends in prescribing among recently treated and newly diagnosed osteoporosis patients?
How have Prolia, Forteo, and Tymlos been integrated into the treatment algorithm?
What proportion of osteoporosis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
What percentage of osteoporosis patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
What are the product-level compliance and persistency rates among drug-treated patients with osteoporosis?